

TMSDRDSI: Drug Design MSc

TMSDRDSING01: MSc Drug Design

WIBRG001, WIBRG002, WIBRG003, WIBRG004, 5 + 6

View Online



Alley, S. C., Okeley, N. M., & Senter, P. D. (2010). Antibody–drug conjugates: targeted drug delivery for cancer. *Current Opinion in Chemical Biology*, 14(4), 529–537.

<https://doi.org/10.1016/j.cbpa.2010.06.170>

Baurin, N., Aboul-Ela, F., Barril, X., Davis, B., Drysdale, M., Dymock, B., Finch, H., Fromont, C., Richardson, C., Simmonite, H., & Hubbard, R. E. (2004). Design and Characterization of Libraries of Molecular Fragments for Use in NMR Screening against Protein Targets. *Journal of Chemical Information and Modeling*, 44(6), 2157–2166.

<https://doi.org/10.1021/ci049806z>

Beck, A., Wurch, T., Bailly, C., & Corvaia, N. (2010). Strategies and challenges for the next generation of therapeutic antibodies. *Nature Reviews Immunology*, 10(5), 345–352.

<https://doi.org/10.1038/nri2747>

Bissantz, C., Kuhn, B., & Stahl, M. (2010). A Medicinal Chemist's Guide to Molecular Interactions. *Journal of Medicinal Chemistry*, 53(14), 5061–5084.

<https://doi.org/10.1021/jm100112j>

Blake, J. F. (2005). Identification and Evaluation of Molecular Properties Related to Preclinical Optimization and Clinical Fate. *Medicinal Chemistry*, 1(6), 649–655.

<https://doi.org/10.2174/157340605774598081>

Bradbury, A. R. M., Sidhu, S., Dübel, S., & McCafferty, J. (2011). Beyond natural antibodies: the power of in vitro display technologies. *Nature Biotechnology*, 29(3), 245–254.

<https://doi.org/10.1038/nbt.1791>

Brignier, A. C., & Gewirtz, A. M. (2010). Embryonic and adult stem cell therapy. *Journal of Allergy and Clinical Immunology*, 125(2), S336–S344.

<https://doi.org/10.1016/j.jaci.2009.09.032>

Castanotto, D., & Rossi, J. J. (2009). The promises and pitfalls of RNA-interference-based therapeutics. *Nature*, 457(7228), 426–433. <https://doi.org/10.1038/nature07758>

Chandra, N. (2009). Computational systems approach for drug target discovery. *Expert Opinion on Drug Discovery*, 4(12), 1221–1236.

<https://doi.org/10.1517/17460440903380422>

Colquhoun, D. (1998). Binding, gating, affinity and efficacy: The interpretation of structure-activity relationships for agonists and of the effects of mutating receptors. *British Journal of Pharmacology*, 125(5), 923–947. <https://doi.org/10.1038/sj.bjp.0702164>

- Congreve, M., Chessari, G., Tisi, D., & Woodhead, A. J. (2008). Recent Developments in Fragment-Based Drug Discovery. *Journal of Medicinal Chemistry*, 51(13), 3661–3680. <https://doi.org/10.1021/jm8000373>
- Copeland, Robert Allen. (2005). Evaluation of enzyme inhibitors in drug discovery: a guide for medicinal chemists and pharmacologists: Vol. Methods of biochemical analysis. J. Wiley. <https://onlinelibrary.wiley.com/doi/book/10.1002/9781118540398>
- Cornish-Bowden, Athel. (2004). Fundamentals of enzyme kinetics (3rd ed). Portland.
- DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003). The price of innovation: new estimates of drug development costs. *Journal of Health Economics*, 22(2), 151–185. [https://doi.org/10.1016/S0167-6296\(02\)00126-1](https://doi.org/10.1016/S0167-6296(02)00126-1)
- Ducry, L., & Stump, B. (2010). Antibody–drug conjugates: Linking cytotoxic payloads to monoclonal antibodies. *Bioconjugate Chemistry*, 21(1), 5–13. <https://doi.org/10.1021/bc9002019>
- Dunlop, J. (2008). High-throughput electrophysiology: an emerging paradigm for ion-channel screening and physiology. *Nature Reviews Drug Discovery*, 7(4), 358–368. <https://doi.org/10.1038/nrd2552>
- Engel, Thomas & Gasteiger, J. (2003). Chemoinformatics: a textbook.
- Fitt, R., & Nodder, E. (2010). Setting the threshold for industrial application: the UK diverges from Europe. *Journal of Intellectual Property Law & Practice*, 5(8), 560–565. <https://doi.org/10.1093/jiplp/jpq061>
- Gasteiger, J. (2003). Handbook of chemoinformatics: from data to knowledge. <https://onlinelibrary.wiley.com/doi/book/10.1002/9783527618279>
- Gibb, Alasdair J., Foreman, John C., & Johansen, Torben. (2011). Textbook of receptor pharmacology (3rd ed). CRC Press.
- Grimm, D. (2009). Small silencing RNAs: State-of-the-art. *Advanced Drug Delivery Reviews*, 61(9), 672–703. <https://doi.org/10.1016/j.addr.2009.05.002>
- Gu, Jenny & Bourne, Philip E. (2008). Structural bioinformatics: Vol. Methods of biochemical analysis (2nd ed). Wiley.
- Holliger, P., & Hudson, P. J. (2005). Engineered antibody fragments and the rise of single domains. *Nature Biotechnology*, 23(9), 1126–1136. <https://doi.org/10.1038/nbt1142>
- Hopkins, A. L., & Groom, C. R. (2002). Opinion: The druggable genome. *Nature Reviews Drug Discovery*, 1(9), 727–730. <https://doi.org/10.1038/nrd892>
- Hopkins, A. L., Groom, C. R., & Alex, A. (2004). Ligand efficiency: a useful metric for lead selection. *Drug Discovery Today*, 9(10), 430–431. [https://doi.org/10.1016/S1359-6446\(04\)03069-7](https://doi.org/10.1016/S1359-6446(04)03069-7)
- Human embryonic stem cells: Derivation, culture, and differentiation: A review. (n.d.).

- Ikura, M., & Inouye, M. (1998). NMR structure of the histidine kinase domain of the *E. coli* osmosensor EnvZ : Article : Nature. Nature, 396(6706), 88–92. <https://doi.org/10.1038/23968>
- Jarnagin, K. (n.d.). Receptor Binding in Drug Discovery. In eLS.
- Jarnagin, K. (2001). Receptor Binding in Drug Discovery. In Encyclopedia of Life Sciences. John Wiley & Sons, Ltd. <https://doi.org/10.1038/npg.els.0000056>
- Jinek, M., & Doudna, J. A. (2009). A three-dimensional view of the molecular machinery of RNA interference. Nature, 457(7228), 405–412. <https://doi.org/10.1038/nature07755>
- Kalluri, R., & Kanasaki, K. (2008). RNA interference: Generic block on angiogenesis. Nature, 452(7187), 543–545. <https://doi.org/10.1038/452543a>
- Kenakin, T. P. (2009). Cellular assays as portals to seven-transmembrane receptor-based drug discovery. Nature Reviews Drug Discovery, 8(8), 617–626. <https://doi.org/10.1038/nrd2838>
- Khawaja, X., Dunlop, J., & Kowal, D. (2008). Scintillation proximity assay in lead discovery. Expert Opinion on Drug Discovery, 3(11), 1267–1280. <https://doi.org/10.1517/17460441.3.11.1267>
- Kola, I., & Landis, J. (2004). Opinion: Can the pharmaceutical industry reduce attrition rates? Nature Reviews Drug Discovery, 3(8), 711–716. <https://doi.org/10.1038/nrd1470>
- Krohn, K. A., & Link, J. M. (2003). Interpreting enzyme and receptor kinetics: keeping it simple, but not too simple. Nuclear Medicine and Biology, 30(8), 819–826. [https://doi.org/10.1016/S0969-8051\(03\)00132-X](https://doi.org/10.1016/S0969-8051(03)00132-X)
- Leach, Andrew R. & Gillet, Valerie J. (2003). An introduction to chemoinformatics.
- Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 23(1–3), 3–25. [https://doi.org/10.1016/S0169-409X\(96\)00423-1](https://doi.org/10.1016/S0169-409X(96)00423-1)
- Lledo, P.-M., Merkle, F. T., & Alvarez-Buylla, A. (2008). Origin and function of olfactory bulb interneuron diversity. Trends in Neurosciences, 31(8), 392–400. <https://doi.org/10.1016/j.tins.2008.05.006>
- Macarron, R., Banks, M. N., Bojanic, D., Burns, D. J., Cirovic, D. A., Garyantes, T., Green, D. V. S., Hertzberg, R. P., Janzen, W. P., Paslay, J. W., Schopfer, U., & Sittampalam, G. S. (2011). Impact of high-throughput screening in biomedical research. Nature Reviews Drug Discovery, 10(3), 188–195. <https://doi.org/10.1038/nrd3368>
- Matter, H. (1997). Selecting Optimally Diverse Compounds from Structure Databases: A Validation Study of Two-Dimensional and Three-Dimensional Molecular Descriptors. Journal of Medicinal Chemistry, 40(8), 1219–1229. <https://doi.org/10.1021/jm960352+>
- Murray, C. W. (2010). Fragment-Based Drug Discovery Applied to Hsp90. Discovery of Two Lead Series with High Ligand Efficiency. Journal of Medicinal Chemistry, 53(16),

5942–5955. <https://doi.org/10.1021/jm100059d>

Murray, C. W., & Rees, D. C. (2009). The rise of fragment-based drug discovery. *Nature Chemistry*, 1(3), 187–192. <https://doi.org/10.1038/nchem.217>

Nagorsen, D., & Baeuerle, P. A. (2011). Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. *Experimental Cell Research*, 317(9), 1255–1260. <https://doi.org/10.1016/j.yexcr.2011.03.010>

Nelson, David L., Cox, Michael M., & Lehninger, Albert L. (2008). *Lehninger principles of biochemistry* (5th ed). W.H. Freeman.

Orengo, Christine Ann, Thornton, Janet M., & Jones, David Tudor. (2003). *Bioinformatics: genes, proteins and computers*. BIOS.
<http://www.vlebooks.com/vleweb/product/openreader?id=UCL&isbn=9780203427828>

Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006). How many drug targets are there? *Nature Reviews Drug Discovery*, 5(12), 993–996. <https://doi.org/10.1038/nrd2199>

Patrick, Graham L. (2017). *An introduction to medicinal chemistry*.

Petsko, Gregory A. & Ringe, Dagmar. (2004). *Protein structure and function: Vol. Primers in biology*. New Science.

Pillay, V., Gan, H. K., & Scott, A. M. (2011). Antibodies in oncology. *New Biotechnology*, 28(5), 518–529. <https://doi.org/10.1016/j.nbt.2011.03.021>

Rang, H. P. & Dale, M. Maureen. (2019). *Pharmacology* (9th ed). Churchill Livingstone.
<https://elsevierelibrary.co.uk/product/9780702074462>

Richard M. Durbin. (2010). A map of human genome variation from population-scale sequencing. *Nature*, 467(7319), 1061–1073. <https://doi.org/10.1038/nature09534>

Schrama, D., Reisfeld, R. A., & Becker, J. C. (2006). Antibody targeted drugs as cancer therapeutics. *Nature Reviews Drug Discovery*, 5(2), 147–159.
<https://doi.org/10.1038/nrd1957>

Selzer, P. M., Rohwer, A., & Marhöfer, R. J. (2008). *Applied bioinformatics: an introduction*. Springer.

Shen, J., Samul, R., Silva, R. L., Akiyama, H., Liu, H., Saishin, Y., Hackett, S. F., Zinnen, S., Kossen, K., Fosnaugh, K., Vargeese, C., Gomez, A., Bouhana, K., Aitchison, R., Pavco, P., & Campochiaro, P. A. (2005). Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. *Gene Therapy*, 13(3), 225–234. <https://doi.org/10.1038/sj.gt.3302641>

Smith, R. A. (2001). Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approach. *Bioorganic & Medicinal Chemistry Letters*, 11(20), 2775–2778.
[https://doi.org/10.1016/S0960-894X\(01\)00571-6](https://doi.org/10.1016/S0960-894X(01)00571-6)

Stadtfeld, M., & Hochedlinger, K. (2010). Induced pluripotency: history, mechanisms, and

applications. *Genes & Development*, 24(20), 2239–2263.
<https://doi.org/10.1101/gad.1963910>

Swinney, D. C., & Anthony, J. (2011). How were new medicines discovered? *Nature Reviews Drug Discovery*, 10(7), 507–519. <https://doi.org/10.1038/nrd3480>

Thomas, Gareth. (2003). *Fundamentals of medicinal chemistry*.

Vaishnaw, A. K., Gollob, J., Gamba-Vitalo, C., Hutabarat, R., Sah, D., Meyers, R., de Fougères, T., & Maraganore, J. (2010). A status report on RNAi therapeutics. *Silence*, 1(1). <https://doi.org/10.1186/1758-907X-1-14>

Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002). Molecular Properties That Influence the Oral Bioavailability of Drug Candidates. *Journal of Medicinal Chemistry*, 45(12), 2615–2623. <https://doi.org/10.1021/jm020017n>

Watt, F. M., & Driskell, R. R. (2010). The therapeutic potential of stem cells. *Philosophical Transactions of the Royal Society B: Biological Sciences*, 365(1537), 155–163.
<https://doi.org/10.1098/rstb.2009.0149>

Webb, S. (2011). Pharma interest surges in antibody drug conjugates. *Nature Biotechnology*, 29(4), 297–298. <https://doi.org/10.1038/nbt0411-297>

Weiner, L. M., Surana, R., & Wang, S. (2010). Monoclonal antibodies: versatile platforms for cancer immunotherapy. *Nature Reviews Immunology*, 10(5), 317–327.
<https://doi.org/10.1038/nri2744>

Welsch, M. E., Snyder, S. A., & Stockwell, B. R. (2010). Privileged scaffolds for library design and drug discovery. *Current Opinion in Chemical Biology*, 14(3), 347–361.
<https://doi.org/10.1016/j.cbpa.2010.02.018>

Wilhelm, S. (2006). Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. *Nature Reviews Drug Discovery*, 5(10), 835–844.
<https://doi.org/10.1038/nrd2130>

Willett, P., Barnard, J. M., & Downs, G. M. (1998). Chemical Similarity Searching. *Journal of Chemical Information and Modeling*, 38(6), 983–996. <https://doi.org/10.1021/ci9800211>

Woodhead, A. J. (2010). Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design. *Journal of Medicinal Chemistry*, 53(16), 5956–5969.
<https://doi.org/10.1021/jm100060b>

Xiong, Jin. (2006). *Essential bioinformatics*. Cambridge University Press.

Zvelebil, Marketa J. & Baum, Jeremy O. (2008). *Understanding bioinformatics*. Garland Science.
https://bibliu.com/app/#/view/books/9781136976964/pdf2html/index.html#page_Cover